Answers are grounded in this paper and cite their sources.
Introduction: Inclusion body myositis is the most common acquired muscle disease affecting older adults. It has an insidious onset with a very specific pattern of muscle involvement, but the aetiopathogenesis is still unknown. Pathologically the combination of inflammatory changes, degenerative changes as well as mitochondrial and nuclear changes are seen, and probably all contribute to the loss of muscle, however the primary abnormality remains a mystery. Treatment is currently supportive, but clinical trials are ongoing and are directed at new targets.Areas covered: Clinical profile, genetic susceptibility, pathogenesis and treatmentExpert opinion: Understanding the aetiopathogeneis is vital to identify future treatment targets. In addition, understanding the natural history and the roles of biomarkers including the anti-CN1a antibody is vital for designing future clinical trials in IBM, to be properly designed and of sufficient duration to detect clinically significant changes.
No takes yet. Share an insight, caveat, or question.
Needham et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: